Published in Head Neck Pathol on December 13, 2011
Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management. J Dermatol Case Rep (2014) 0.91
Oral mucosal melanoma: some pathobiological considerations and an illustrative report of a case. Head Neck Pathol (2014) 0.89
Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas. Oncotarget (2015) 0.76
Unknown primary nasopharyngeal melanoma presenting as severe recurrent epistaxis and hearing loss following treatment and remission of metastatic disease: A case report and literature review. Int J Surg Case Rep (2015) 0.75
Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma. Oncotarget (2017) 0.75
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76
Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet (1992) 1.69
Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res (1992) 1.60
Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer (2004) 1.51
Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A (1996) 1.45
Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med (2003) 1.28
INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene (2001) 1.23
p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg (2002) 1.17
Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci (1999) 1.13
Expression of mutant p53 in melanoma. Cancer Res (1991) 1.10
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer (1995) 1.07
Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer (1997) 1.02
Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck. Am J Surg Pathol (2002) 1.01
Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol (2001) 1.00
Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer (2006) 0.95
Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck (2004) 0.95
Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol (2002) 0.94
p16 gene methylation in colorectal cancers associated with Duke's staging. World J Gastroenterol (2001) 0.93
p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol (1995) 0.93
Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer (2002) 0.89
Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer (1998) 0.87
p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol (1995) 0.85
Expression of Rb, pRb2/p130, p53, and p16 proteins in malignant melanoma of oral mucosa. Oral Oncol (2001) 0.85
Expression of p53 protein in cutaneous melanoma. Int J Cancer (1992) 0.84
bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology (1999) 0.83
Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. Int J Oncol (2002) 0.83
p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology (1997) 0.82
Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg (1999) 0.82
p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Mod Pathol (1994) 0.81
Primary mucosal desmoplastic melanoma of the head and neck. Head Neck (2004) 0.81
The CDKN2A tumor-suppressor locus--a tale of two proteins. N Engl J Med (1998) 0.80
Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma. Bosn J Basic Med Sci (2010) 0.79
p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin. Melanoma Res (2004) 0.79
Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. Tumori (2001) 0.78
Expression of p16 in sinonasal malignant melanoma. Virchows Arch (2006) 0.77
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid (2014) 2.31
Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg (2002) 2.08
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin (2005) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer (2003) 1.94
The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg (2006) 1.90
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2011) 1.80
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer (2006) 1.79
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol (2006) 1.78
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2010) 1.77
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol (2005) 1.76
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol (2003) 1.74
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg (2003) 1.74
Management of well-differentiated thyroid carcinoma presenting within a thyroglossal duct cyst. J Surg Oncol (2002) 1.73
Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther (2007) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol (2010) 1.70
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med (2007) 1.69
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med (2008) 1.65
Head and neck cancers. J Natl Compr Canc Netw (2011) 1.64
Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol (2007) 1.63
Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study. Cancer (2007) 1.63
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2009) 1.58
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery (2007) 1.54
Head and neck soft tissue sarcomas: a multivariate analysis of outcomes. Ann Surg Oncol (2004) 1.51
Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer (2004) 1.51
Merkel cell carcinoma: histologic features and prognosis. Cancer (2008) 1.50
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med (2006) 1.46
Two cases of multiple spitz nevi: correlating clinical, histologic, and fluorescence in situ hybridization findings. Arch Dermatol (2011) 1.44
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J (2006) 1.42
Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg (2012) 1.41
A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.39
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck (2005) 1.39
The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol (2004) 1.39
FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol (2006) 1.37
Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst (2010) 1.36
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol (2013) 1.36
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.35
In vivo reflectance confocal microscopy imaging of melanocytic skin lesions: consensus terminology glossary and illustrative images. J Am Acad Dermatol (2007) 1.33
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2007) 1.33
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck (2002) 1.32
Decision making in the management of recurrent head and neck cancer. Head Neck (2013) 1.31
Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck (2005) 1.31
Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer (2009) 1.30
Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg (2002) 1.29
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys (2006) 1.29
Genome-wide appraisal of thyroid cancer progression. Am J Pathol (2002) 1.28
Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med (2003) 1.28
Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys (2008) 1.27
CO2 laser cordectomy for early-stage glottic carcinoma: a long-term follow-up of 156 cases. Laryngoscope (2002) 1.26
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer (2002) 1.26
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys (2011) 1.26
Malignant minor salivary gland tumors of the larynx. Arch Otolaryngol Head Neck Surg (2006) 1.25
Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg (2006) 1.25
Re: Extent of surgery affects papillary thyroid cancer. Ann Surg (2008) 1.23
Solitary fibrous tumors of the head and neck: a clinicopathologic and radiologic review. Arch Otolaryngol Head Neck Surg (2006) 1.23
Incidence of inadvertent parathyroid removal during thyroidectomy. Laryngoscope (2002) 1.22
Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol (2002) 1.22
Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer (2006) 1.22
Management issues in massive pediatric facial plexiform neurofibroma with neurofibromatosis type 1. Head Neck (2002) 1.20
Lymph node density is a significant predictor of outcome in patients with oral cancer. Cancer (2009) 1.20
Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes Control (2011) 1.20
The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid (2012) 1.19
Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer (2006) 1.19
Reflectance confocal microscopy of pigmented basal cell carcinoma. J Am Acad Dermatol (2006) 1.19